Dr. Brammer on Updates in the Treatment Landscape for T-Cell Lymphoma
Jonathan E. Brammer, MD
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.
T-cell lymphoma has been an area of limited progress and poor prognosis, according to Brammer. An exciting development is with brentuximab vedotin (Adcetris), which is now being utilized for patients with relapsed CD30-positive anaplastic large-cell lymphoma. Some of those patients have long-term durable remissions.
For patients with cutaneous T-cell lymphoma, brentuximab vedotin is also highly effective, adds Brammer.